BillionToOne Reports Strong Q4 & FY25 Results, Achieves Profitability, and Raises 2026 Revenue Guidance
summarizeSummary
BillionToOne, Inc. announced strong Q4 and full year 2025 financial results, achieving profitability and significantly raising its full year 2026 revenue guidance.
check_boxKey Events
-
Achieved Significant Revenue Growth
Total revenue increased 113% year-over-year to $96.1 million in Q4 2025 and 100% to $305.1 million for the full year 2025, driven by strong growth in both prenatal and oncology clinical testing.
-
Shifted to Operating and Net Profitability
The company reported an operating income of $10.3 million in Q4 2025 (vs. $11.7 million operating loss in Q4 2024) and $16.0 million for the full year 2025 (vs. $47.1 million operating loss in 2024). Net income was also positive for both periods.
-
Raised Full Year 2026 Revenue Guidance
BillionToOne raised its 2026 full year revenue guidance to a range of $430 million to $445 million, up from previous guidance of $415 million to $430 million, representing 41% to 46% growth over 2025. The company also expects positive GAAP operating income for full year 2026.
-
Introduced New Employee Incentive Plan
The Board approved an Annual Incentive Plan, effective January 1, 2026, designed to attract, retain, and motivate top-performing employees through cash or fully vested stock bonuses.
auto_awesomeAnalysis
BillionToOne, Inc. reported exceptionally strong financial results for both the fourth quarter and full year 2025, marking a significant turnaround to profitability. The company achieved substantial revenue growth, with Q4 revenue increasing 113% year-over-year and full-year revenue doubling. Crucially, BillionToOne transitioned from significant operating losses in 2024 to positive operating income in both Q4 and the full year 2025, and also reported positive net income. This strong performance is further underscored by raised revenue guidance for full year 2026, projecting continued robust growth and sustained profitability. The introduction of new prenatal and oncology products in Q1 2026 also signals ongoing innovation and market expansion. This filing fundamentally shifts the investment thesis, demonstrating the company's ability to scale profitably.
At the time of this filing, BLLN was trading at $85.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $66.00 to $138.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.